Google
Trusted Resources: News & Events
Latest announcements and gatherings
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell Trial
Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell patients 5 to 17 years old. Altemia is a combination of specific lipids designed to restore balance to the membrane of red blood cells that are damaged in sickle cell disease patients. The therapy uses Sancilio’s proprietary Advanced Lipid Technologies (ALT) platform.
The Phase 2 trial (NCT02973360) primary endpoint was the change from baseline in the concentration of fatty acids in the red blood cell membrane of patients treated with one of the three active doses of Altemia, or matching placebo. Fatty acids are a major component of cellular membrane.
+myBinderRelated Content
-
Effects of Hydroxyurea Treatment for Patients With Hemoglobin SC DiseaseAlthough hemoglobin SC (HbSC) disease is...
-
Global Blood Therapeutics (GBT) announces upcoming data presentations supporting Voxelotor SCD programGlobal Blood Therapeutics, Inc. (GBT) ...
-
Hemoglobin A1c and Fructosamine Correlate in a Patient With Sickle Cell Disease And Diabetes on Chronic Transfusion ...In patients with sickle cell disease (SC...
-
Sickle Cell Treatment Endari Now Available in the United StatesEmmaus Life Sciences has announced that ...
-
LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data ReportsBluebird bio presented new positive resu...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Sequence Replacement to Cure Sickle Cell DiseaseNext-generation gene editing is already ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.